Simple test predicts diabetes remission following weight loss surgery

November 21, 2017

A new simple test that helps predicts which people with type 2 diabetes will benefit most from weight loss surgery has been developed by a UCL-led team.

The study, published today in Diabetic Medicine, also reports that keeping the weight off after bariatric surgery is more important than which type of weight loss operation was done. Taken together, the findings should help maximise the health benefits obtained from weight loss surgery.

"Over 2 million people in the UK are eligible for assessment for bariatric surgery, and yet only 6,000 undergo the procedure each year. Given the limited access to surgery it's vital that we ensure it's offered to those who will benefit the most, and that they're well supported long after the surgery," said the study's lead author, Professor Rachel Batterham (UCL Centre for Obesity Research and UCLH Bariatric Centre for Weight Management and Metabolic Surgery).

Type 2 diabetes (T2D) is currently estimated to cause close to 25,000 preventable deaths a year in the UK, and the main driver for its increased prevalence is rising obesity rates. Sustained weight loss improves blood glucose control in people with established T2D; however, maintaining sustained weight loss is difficult due to biological compensatory mechanisms.

Bariatric surgery alters the hormones that control blood glucose, lowering glucose levels and reducing the long-term complications of T2D such as eye and kidney damage. Many people with T2D are able to stop all of their diabetes medications after surgery. Bariatric surgery is now recognised as a treatment option for people with T2D with a BMI of 35 or above.

"Bariatric surgery can be highly beneficial, yet the results are highly variable, so we set out to devise a better way of identifying which people with T2D will benefit most," explained Professor Batterham, who also leads the Obesity research theme at the University College London Hospitals Biomedical Research Centre.

The study was a retrospective cohort study of people with T2D who had undergone Roux-en-Y gastric bypass surgery (107 people) or sleeve gastrectomy (103 people), with two-year follow-up data, plus a further 173 people in a separate study to validate the results. The researchers employed two scoring systems designed to predict T2D remission post-surgery: the established DiaRem score, as well as the novel, more accessible DiaBetter score designed by the research team.

The DiaBetter score is calculated from three factors: the drugs a person is currently taking, their HbA1c level (a simple blood test used to monitor blood glucose in all people with diabetes) and how long ago their diabetes was diagnosed.

People with low DiaRem scores were significantly more likely to achieve T2D remission than those with higher scores. Remission rates among those in the lowest quintile of DiaBetter scores were 98% compared to 19% in the highest quintile.

The researchers also found that percentage weight loss two years post-surgery was a stronger predictor of T2D remission than whether the patient underwent gastric bypass or sleeve gastrectomy, as there wasn't a significant difference between the two surgeries after adjusting for weight loss.

For every 5% weight loss, the odds of T2D remission increased by 54%. It was the first time the significance of weight loss to remission was established in people who had undergone sleeve gastrectomy; while it's the most common type of bariatric surgery globally, it's much newer than gastric bypass so there are gaps in the research.

"Access to bariatric surgery is very carefully controlled, yet post-surgery support is often lacking. We've added to the evidence that it's vital to support people in maintaining their weight loss long-term, to make sure that the surgery is effective," said Dr Andrea Pucci (UCL Centre for Obesity Research and UCLH Bariatric Centre for Weight Management and Metabolic Surgery), the study's first author.

"As roughly one in five people don't have positive results from bariatric surgery, we hope that clinicians will begin using DiaBetter right away to adequately weigh the benefits and risks, and ensure that only the most suitable candidates have the surgery," said Professor Batterham.
-end-
The study was conducted at UCLH by researchers at UCL, UCLH, Imperial College Healthcare NHS Trust, the University of Alexandria, Centro Hospitalar de Entre o Douro e Vouga, and the University of Porto, and was funded by the Robert Luff Foundation, the Rosetrees Trust, the National Institute for Health Research, and the Sir Jules Thorn Charitable Trust.

University College London

Related Diabetes Articles from Brightsurf:

New diabetes medication reduced heart event risk in those with diabetes and kidney disease
Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

Read More: Diabetes News and Diabetes Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.